Drug Profile

CS TATI 1

Alternative Names: CS-TATI-1

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cannabis Science
Class Antiretrovirals
Mechanism of Action Cannabinoid receptor modulators; Human immunodeficiency virus tat gene product inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2015 Preclinical trials in HIV infections in USA (unspecified route) prior to May 2015
27 May 2015 Cannabis Science and IGXBio agree to co-promote and co-develop CS TATI 1 in combination with GenePro® in USA for HIV infections and Inflammation
27 May 2015 Cannabis Science plans to initiated phase I/II trial for HIV infection (In combination therapy)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com